ULTOMIRIS® (ravulizumab-cwvz) approved in the US for th

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+ NMOSD the potential to live relapse-free


Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial...

Related Keywords

United Kingdom , New Zealand , Hungary , Japan , United States , Boston , Massachusetts , Australia , Cambridge , Cambridgeshire , Shiga , America , Neuromyelitis Optica , Histochem Cytochem , Astrazeneca , Alexion Pharmaceuticals Inc , Drug Administration , Nasdaq , Paroxysmal Nocturnal Hemoglobinuria , Hemolytic Uremic Syndrome , Myasthenia Gravis , Neuromyelitis Optica Spectrum Disorder , Patient Safety Card , Mitigation Strategy , Prescribing Information , Medication Guide , North America , Expanded Disability Status Scale Score , Astrazeneca Rare Disease , Alexion Pharmaceuticals , Rare Diseases , Treat Options , South East , Neurol Neurosurg , Neuromyelitis Optica Spectrum Disorder Using , Safety Study , Adult Participants With ,